Cite

HARVARD Citation

    Chen, C. et al. (2022). A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C. JGH open. 6 (11), pp. 782-791. [Online]. 
  
Back to record